Mereo Biopharma Group Plc ADR (MREO) Stock Price, Quote & News

Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 33 3023 7300

Website: www.mereobiopharma.com

Address:

One Cavendish Place, 4th Floor, London, United Kingdom

davedtire Aug. 29 at 1:27 AM

$MREO this is where Denise shines . The fireside chat

4 · Reply

davedtire Aug. 29 at 1:21 AM

$MREO https://x.com/semodough/status/1961236275568210134?s=12&t=YEJOuteXsdU9zZ7HW8_OFw

0 · Reply

Newcar Aug. 28 at 5:12 PM

$MREO It won't move until the final data from the Phase 3 clinical trial on setrusumab are released in the next few months...We need to wait and be patient for the next 2-3 months.

0 · Reply

mds04086 Aug. 28 at 2:33 PM

$MREO short interest getting higher, if this gets news and volume, there's a huge gap that can be filled just above us

0 · Reply

TragicRain Aug. 27 at 4:55 PM

$MREO - CUP/HANDLE -

2 · Reply

Newcar Aug. 27 at 2:31 PM

$MREO J.P. Morgan : price target $8

0 · Reply

Berakhot Aug. 26 at 4:14 PM

$MREO nice..., good find https://www.gurufocus.com/news/3077312/mreo-sees-price-target-raised-to-8-by-jp-morgan-mreo-stock-news

0 · Reply

cheetohottaki Aug. 25 at 1:06 PM

$MREO https://x.com/revshark/status/1959953880155893850?s=46

0 · Reply

ScottyDoesntKnowMeSon Aug. 25 at 12:07 PM

$MREO power that be get enough cheapies to finally move it?

2 · Reply

lidopete Aug. 25 at 11:37 AM

$MREO Mereo BioPharma price target raised to $8 from $7 at JPMorgan JPMorgan raised the firm's price target on Mereo BioPharma to $8 from $7 and keeps an Overweight rating on the shares. The firm updated the company's model.

0 · Reply

āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

Aug 12, 2025, 7:35 AM EDT - 18 days ago

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Jul 10, 2025, 3:15 PM EDT - 7 weeks ago

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI

May 13, 2025, 7:30 AM EDT - 3 months ago

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

Mar 26, 2025, 7:30 AM EDT - 5 months ago

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Mar 5, 2025, 7:30 AM EST - 6 months ago

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

Jan 12, 2025, 11:05 AM EST - 8 months ago

Mereo BioPharma Provides Update on Lead Clinical Programs

Jan 7, 2025, 7:30 AM EST - 8 months ago

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 26, 2024, 1:36 PM EST - 9 months ago

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Nov 14, 2024, 7:30 AM EST - 10 months ago

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Nov 12, 2024, 7:30 AM EST - 10 months ago

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Sep 12, 2024, 5:35 PM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 14, 2024, 7:50 AM EDT - 1 year ago

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

May 30, 2024, 7:30 AM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

May 15, 2024, 4:01 PM EDT - 1 year ago

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 3, 2024, 7:30 AM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 5:34 PM EDT - 1 year ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRRO KRYS TAK WVE

Mar 5, 2024, 7:30 AM EST - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

Jan 8, 2024, 7:00 AM EST - 1 year ago

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Oct 23, 2023, 4:01 PM EDT - 2 years ago

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

Sep 7, 2023, 7:30 AM EDT - 2 years ago

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

May 31, 2023, 7:00 AM EDT - 2 years ago

Mereo BioPharma to Present at the Jefferies Healthcare Conference

May 23, 2023, 1:43 PM EDT - 2 years ago

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

May 8, 2023, 12:46 PM EDT - 2 years ago

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 5, 2023, 4:06 PM EDT - 2 years ago

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

Mar 28, 2023, 4:30 PM EDT - 2 years ago

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

Mar 21, 2023, 6:30 AM EDT - 2 years ago

Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

Feb 8, 2023, 7:00 AM EST - 2 years ago

Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

Nov 2, 2022, 4:01 PM EDT - 3 years ago

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

Oct 28, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

Oct 24, 2022, 4:30 PM EDT - 3 years ago

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

Oct 21, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

Oct 18, 2022, 11:58 AM EDT - 3 years ago

Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

Oct 18, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value

Oct 17, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Oct 3, 2022, 5:00 PM EDT - 3 years ago

Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

Oct 3, 2022, 9:00 AM EDT - 3 years ago

Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five

Sep 26, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board

Sep 22, 2022, 1:45 PM EDT - 3 years ago

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

Sep 14, 2022, 9:00 AM EDT - 3 years ago

Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders

Sep 12, 2022, 8:00 AM EDT - 3 years ago

Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors

Aug 31, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Sends Letter to Rubric Capital Management

Jun 17, 2022, 10:39 AM EDT - 3 years ago

Why Mereo BioPharma Shares Are Jumping Today

Jun 17, 2022, 3:44 AM EDT - 3 years ago

AstraZeneca weighing bid for Mereo BioPharma: report

AZN

May 26, 2022, 5:05 PM EDT - 3 years ago

Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting

davedtire Aug. 29 at 1:27 AM

$MREO this is where Denise shines . The fireside chat

4 · Reply

davedtire Aug. 29 at 1:21 AM

$MREO https://x.com/semodough/status/1961236275568210134?s=12&t=YEJOuteXsdU9zZ7HW8_OFw

0 · Reply

Newcar Aug. 28 at 5:12 PM

$MREO It won't move until the final data from the Phase 3 clinical trial on setrusumab are released in the next few months...We need to wait and be patient for the next 2-3 months.

0 · Reply

mds04086 Aug. 28 at 2:33 PM

$MREO short interest getting higher, if this gets news and volume, there's a huge gap that can be filled just above us

0 · Reply

TragicRain Aug. 27 at 4:55 PM

$MREO - CUP/HANDLE -

2 · Reply

Newcar Aug. 27 at 2:31 PM

$MREO J.P. Morgan : price target $8

0 · Reply

Berakhot Aug. 26 at 4:14 PM

$MREO nice..., good find https://www.gurufocus.com/news/3077312/mreo-sees-price-target-raised-to-8-by-jp-morgan-mreo-stock-news

0 · Reply

cheetohottaki Aug. 25 at 1:06 PM

$MREO https://x.com/revshark/status/1959953880155893850?s=46

0 · Reply

ScottyDoesntKnowMeSon Aug. 25 at 12:07 PM

$MREO power that be get enough cheapies to finally move it?

2 · Reply

lidopete Aug. 25 at 11:37 AM

0 · Reply

LQQKER_INSIDER Aug. 23 at 10:13 PM

$MREO

0 · Reply

poot_buttagina Aug. 22 at 9:21 PM

$MREO Not a single sell in the last 4 min. of trading, all neutral and buys on a friday looks positive for next week. Holding a stake at $1.61 with a few middated calls. Glta

0 · Reply

Mjcwo Aug. 22 at 12:33 PM

$MREO slowly accumulating here, this will rip soon.

1 · Reply

Berakhot Aug. 21 at 2:44 PM

$MREO Added, opportunity on every drop.

0 · Reply

Newcar Aug. 21 at 2:13 PM

$MREO If news of a delay in the approval of setrusumab were to come out... there could be a drop of up to 50%. In that case, I would double my shares.

1 · Reply

Mjcwo Aug. 20 at 4:18 AM

$MREO super

0 · Reply

LDT79 Aug. 19 at 3:41 PM

$MREO why can't they sack the CEO??

0 · Reply

Berakhot Aug. 19 at 3:35 PM

$MREO added shares

0 · Reply

Berakhot Aug. 19 at 3:30 PM

$MREO Missed this, great find! - Company’s second clinical-stage asset licensed from Mereo Biopharma based on novel insights generated in a mouse model of osteopetrosis - - āshibio has exclusive license to develop and commercialize vantictumab globally, excluding Europe, where Mereo retains commercial rights - - Vantictumab development program is supported by safety and biomarker data generated in previous clinical trials...

0 · Reply

Berakhot Aug. 19 at 3:26 PM

$MREO a) Looking back to June 2024 Phase 2/3 Orbiit data by MREO & RARE led to eventual high of $5. b) October 2024: "FDA granted Breakthrough Therapy Designation for setrusumab, targeting fracture risk reduction in OI Types I, III, and IV."

1 · Reply

LDT79 Aug. 19 at 2:11 PM

$MREO • Europe's population: ~750 million • Prevalence of ADO2: 1 in 20,000 • Average annual treatment: $15,000 (TAM) for Autosomal Dominant Osteopetrosis Type 2 (ADO2) in Europe is: • Estimated patient population: 37,500 • TAM: $562.5 million annually

0 · Reply

EddieH2020 Aug. 19 at 1:12 PM

$MREO Nice find ..

1 · Reply

Market Cap	530.17M
Revenue (ttm)	10.00M
Net Income (ttm)	-29.47M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	28,075
Avg Vol	812,584
Day's Range	N/A - N/A
Shares Out	140.26M
Stochastic %K	30%
Beta	0.88
Analysts	Strong Sell
Price Target	$6.80